Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/archdischild-2019-318447 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MELANOMA AND DYSPLASTIC NEVI DEVELOPMENT AFTER RANITIDINE/RILMENIDINE/МOXONIDINE, LERCANIDIPINE, ROSUVASTATIN AND VERAPAMIL/TRANDOLAPRIL - NEW DATA/CASE SERIES. THE POTENTIAL ROLE OF NITROSAMINE/NDSRIS CONTAMINATION IN POLYMEDICATION AS SUBSTANTIAL SKIN CANCER TRIGGERING FACTOR.
Georgian Med News
November 2023
2Department of Dermatology and Venereology, Medical Institute of Ministry of Interior, Sofia, Bulgaria.
Article Synopsis
- - The concept of drug-induced Nitrosogenesis suggests that long-term exposure to nitrosamines in medications may contribute to cancer, particularly melanoma, which has been linked to drugs like Valsartan and Hydrochlorothiazide.
- - Recent studies have detected potential contamination with carcinogenic nitrosamines in newer medications, including Ranitidine and Rosuvastatin, indicating a broader risk linked to a variety of drugs.
- - Researchers emphasize the need for further exploration of nitrosamines' role in drug-related cancer risks, highlighting the necessity for the scientific community to clarify dosage and exposure levels associated with both combination and single medication use.
Ultrasmall nitrogen-doped CuCoO nanocrystal-decorated cerium dioxide nanoparticles for fast and complete degradation of ranitidine via permonosulfate activation.
Chemosphere
June 2023
Institute for Ecological Research and Pollution Control of Plateau Lakes, School of Ecology and Environmental Science, Yunnan University, Kunming, 650504, China. Electronic address:
A simple and efficient coagulation method was used for the rapid preparation of nitrogen-doped copper-cobalt oxide (N-CuCoO) supported on cerium dioxide (CeO), that is, N-CuCoO@CeO. A low concentration of N-CuCoO@CeO (0.15 g L) was shown to rapidly activate permonosulfate (PMS) (0.
View Article and Find Full Text PDFPharmacological interventions for prevention of weight gain in people with schizophrenia.
Cochrane Database Syst Rev
October 2022
Complex Care and Recovery, Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada.
Article Synopsis
- Antipsychotic-induced weight gain is prevalent among individuals with schizophrenia, leading to serious health complications, prompting the need for effective management strategies.
- This review aims to evaluate the effectiveness of pharmacological interventions specifically designed to prevent weight gain associated with antipsychotic medications in schizophrenia patients.
- The review includes 17 randomized controlled trials and assesses various outcomes related to weight changes and compliance, although many of the primary outcomes were infrequently reported in the studies.
The efficacy and safety of the short-term combination therapy with ticagrelor and PPIs or H2RA in patients with acute STEMI who underwent emergency PCI.
Clin Transl Sci
February 2022
Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Combination therapy with platelet inhibitors and acid-suppressive agents is recommended for patients with acute ST-segment elevation myocardial infarction (STEMI) who underwent percutaneous coronary intervention (PCI), but there remains a paucity of data to evaluate both the efficacy and safety of these combinations. In this prospective study, a total of 170 patients with acute STEMI who underwent PCI were divided into four groups: pantoprazole + ticagrelor, omeprazole + ticagrelor, ranitidine + ticagrelor, and ticagrelor only. The risk of PCI, antithrombotic efficacy, cardiac function, and main end points were evaluated and compared.
View Article and Find Full Text PDFDesign, development and optimization of sustained release floating, bioadhesive and swellable matrix tablet of ranitidine hydrochloride.
PLoS One
November 2021
Department of Pharmaceutics and Social Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Ranitidine HCl, a selective, competitive histamine H2-receptor antagonist with a short biological half-life, low bioavailability and narrow absorption window, is an ideal candidate for gastro-retentive drug delivery system (GRDDS). Controlled release with an optimum retentive formulation in the upper stomach would be an ideal formulation for this drug. The aim of the present study was therefore to develop, formulate and optimize floating, bioadhesive, and swellable matrix tablets of ranitidine HCl.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!